Payment overview · 2025
General Payments
$2,347.37
46 reported records · 8 companies
Healthcare provider profile · identity verified
Paul H Le, MD
Allopathic & Osteopathic Physicians|Pain Medicine|Interventional Pain Medicine · AUSTIN, TX · NPI 1770766313
Verified facts
What the public records show
CMS Open Payments records show Paul H Le, MD received $2,347.37 in general payments during 2025 across 46 reported records.
Medtronic, Inc. accounted for 48.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,144.11 | 48.7% | 15 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $443.51 | 18.9% | 13 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $337.19 | 14.4% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $155.45 | 6.6% | 3 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $151.96 | 6.5% | 8 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $52.49 | 2.2% | 1 | 2025 |
| Curonix LLC | Unresolved — no canonical attribution shown | $34.63 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.03 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,347.37 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $487.87 | 4 | 2025 |
Source payment records
|
|||||
| PRIMEADVANCED SURESCAN Normalized: primeadvanced surescan |
Device | Medtronic, Inc. | $463.63 | 6 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $248.34 | 3 | 2025 |
Source payment records
|
|||||
| OCTRODE Normalized: octrode |
Device | Abbott Laboratories | $183.34 | 3 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $155.45 | 3 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $151.96 | 8 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $134.01 | 4 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $126.16 | 6 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $105.89 | 2 | 2025 |
Source payment records
|
|||||
| OMNIA Normalized: omnia |
Device | Globus Medical, Inc. | $88.85 | 1 | 2025 |
Source payment records
|
|||||
| VANTA ADAPTIVESTIM Normalized: vanta adaptivestim |
Device | Medtronic, Inc. | $57.64 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $52.49 | 1 | 2025 |
Source payment records
|
|||||
| PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A Normalized: pns freedom 4a permanent neurostimulator receiver kit channel a |
Device | Curonix LLC | $34.63 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $28.03 | 1 | 2025 |
Source payment records
|
|||||
| ASCENDA Normalized: ascenda |
Device | Medtronic, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| MEDTRONIC REUSABLE INSTRUMENTS Normalized: medtronic reusable instruments |
Device | Medtronic, Inc. | $7.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 2872 | 635 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 633 | 177 |
| Oxycodone Hcl | Oxycodone Hcl | 617 | 164 |
| Morphine Sulfate Er | Morphine Sulfate | 527 | 105 |
| Hydromorphone Hcl | Hydromorphone Hcl | 295 | 76 |
| Gabapentin | Gabapentin | 234 | 89 |
| Fentanyl | Fentanyl | 103 | 26 |
| Tramadol Hcl | Tramadol Hcl | 101 | 53 |
| Xtampza Er | Oxycodone Myristate | 101 | 22 |
| Oxycontin | Oxycodone Hcl | 94 | 23 |
| Pregabalin | Pregabalin | 91 | 47 |
| Buprenorphine | Buprenorphine | 87 | 32 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 85 | 43 |
| Buprenorphine Hcl | Buprenorphine Hcl | 78 | 25 |
| Morphine Sulfate | Morphine Sulfate | 78 | 20 |
| Meloxicam | Meloxicam | 70 | 27 |
| Cephalexin | Cephalexin | 64 | 57 |
| Methadone Hcl | Methadone Hcl | 63 | 14 |
| Baclofen | Baclofen | 60 | 21 |
| Methocarbamol | Methocarbamol | 59 | 23 |
| Belbuca | Buprenorphine Hcl | 57 | 18 |
| Lactulose | Lactulose | 56 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 24 |
| Tramadol Hcl Er | Tramadol Hcl | 43 | 16 |
| Methylprednisolone | Methylprednisolone | 36 | 33 |
| Ibuprofen | Ibuprofen | 30 | 12 |
| Nucynta | Tapentadol Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Hydrocodone Bitartrate Er | Hydrocodone Bitartrate | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 18 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Hydromorphone Er | Hydromorphone Hcl | 14 | suppressed |
| Nucynta Er | Tapentadol Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,347.37 · 46 records | Medtronic, Inc. | ASCENDA, BOTOX, General - Pain Management, INCEPTIV, INFINITY, INSPIRE, MEDTRONIC REUSABLE INSTRUMENTS, OCTRODE, OMNIA, PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A, PRIMEADVANCED SURESCAN, PROCLAIM, ROXYBOND, SYNCHROMEDII, Senza, VANTA ADAPTIVESTIM | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error